Merck & Co., Ariad's ridaforolimus meets goal of mid-stage endometrial cancer study

Merck & Co.'s partner, Ariad Pharmaceuticals, reported Monday that in a mid-stage trial, the experimental mTOR inhibitor, ridaforolimus, showed a significant improvement in median progression-free survival (PFS) in patients with metastatic or recurrent endometrial cancer, compared to those treated with standard therapy. The interim data were presented at the International Gynecologic Cancer Society meeting. Eric Rubin, vice president of Merck's cancer research laboratories, said that "based on these data indicating a statistically significant improvement in the trial's primary endpoint of PFS, Merck has stopped further enrollment in the trial, while continuing to follow surviving patients."
Reference Articles
Ariad announces interim results from randomized Phase 2 trial of oral ridaforolimus in advanced endometrial cancer - (ARIAD)
Ariad, Merck cancer drug impresses in study - (Fidelity)
Ariad announces positive interim results for endometrial cancer drug, share rise - (Stock Markets Review)
Ariad Pharma cancer drug meets midstage study goal - (Yahoo!Finance)
**Published in "First Word"